Moleculin Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Moleculin Biotech, Inc. (MBRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2020-08-12
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-12-31 was $15.75K.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-09-30 was -$6.80M.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-06-30 was $6.80M.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $15.75K.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $83.00K, a 69.87% decline from fiscal 2016.
- Moleculin Biotech, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $275.50K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2020-06-30 | $0.00 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | $15.75K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | -$6.78M derived: sum of 2 quarters · filed 2020-03-19 | $15.75K derived: sum of 3 quarters · filed 2020-03-19 | $15.75K 10-K · filed 2020-03-19 |
| 2019-09-30 | -$6.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $6.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-16 | $6.80M 10-Q · filed 2019-08-16 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-13 | |||
| 2018-09-30 | -$9.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$10.00K derived: sum of 2 quarters · filed 2018-11-13 | $70.00K 10-Q · filed 2018-11-13 | $35.70K derived: sum of 4 quarters · filed 2018-11-13 |
| 2018-06-30 | -$500.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $79.50K 10-Q · filed 2018-08-10 | $45.20K derived: sum of 3 quarters · filed 2018-08-10 | $79.00K derived: sum of 4 quarters · filed 2018-08-10 |
| 2018-03-31 | $80.00K 10-Q · filed 2018-05-14 | $45.70K derived: sum of 2 quarters · filed 2018-05-14 | $79.50K derived: sum of 3 quarters · filed 2018-05-14 | $114.50K derived: sum of 4 quarters · filed 2018-05-14 |
| 2017-12-31 | -$34.30K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | -$500.00 derived: sum of 2 quarters · filed 2018-03-28 | $34.50K derived: sum of 3 quarters · filed 2018-03-28 | $83.00K 10-K · filed 2018-03-28 |
| 2017-09-30 | $33.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $68.80K derived: sum of 2 quarters · filed 2017-11-13 | $117.30K 10-Q · filed 2017-11-13 | $117.30K derived: sum of 4 quarters · filed 2017-11-13 |
| 2017-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $83.50K 10-Q · filed 2017-08-11 | $83.50K derived: sum of 3 quarters · filed 2017-08-11 | |
| 2017-03-31 | $48.50K 10-Q · filed 2017-05-12 | $48.50K derived: sum of 2 quarters · filed 2017-05-12 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-03 | $275.50K 10-K · filed 2017-04-03 | ||
| 2016-09-30 | $275.50K 10-Q · filed 2016-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |